Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.
Chao H. Huang, MD, FACP
Advertisement
Articles by Chao H. Huang, MD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
5